Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
305 results about "Reverse genetics" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Reverse genetics is a method that is used to help understand the function of a gene by analyzing the phenotypic effects of specific engineered gene sequences. Reverse genetics usually proceeds in the opposite direction of so-called forward genetic screens of classical genetics. In other words, while forward genetics seeks to find the genetic basis of a phenotype or trait, reverse genetics seeks to find what phenotypes arise as a result of particular genetic sequences.
Screening for west nile virus antiviral therapy
InactiveUS20050058987A1Improve efficiencySsRNA viruses positive-senseVectorsHigh-Throughput Screening MethodsImmunogenicity
The instant invention provides stable and novel lineage I WNV reverse genetics systems, and methods for making the reverse genetics systems, specifically, a fully-infectious lineage I WNV cDNA or replicon system engineered with one or more nucleotide sequences each encoding a reporter gene to be used in high throughput cell-based screening assays for the identification of novel antiflaviviral chemotherapeutics and / or vaccines effective to treat and / or immunize against infections by WNV and other emerging flaviviruses, such as, for example, JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV and MVEV. The present invention further provides methods of high throughput screening of antiflaviviral compounds or improved derivatives thereof using novel lineage I WNV reverse genetics systems and / or cell lines stably containing the reverse genetics systems. Also, the invention provides novel pharmaceutical compositions comprising an attenuated lineage I WNV that is less virulent but similarly immunogenic as the parent WNV and is capable of providing a protective immune response in a host.
Owner:HEALTH RES INC
Gene ó¸ type new castle disease virus weakening strain A-NDV-ó¸ and construction method thereof
ActiveCN101182494AHigh reproductive titerSuitable for mass productionInactivation/attenuationNewcastle disease virus NDVGene type
A VII gene type of an attenuated strain of Newcastle disease virus A-NDV-VII and a construction method are disclosed. The invention relates to the application of reverse genetics technique. The invention uses the constructed reverse genetics platform of ZJ1 strain of Newcastle disease virus of goose origin. The invention replaces two envelope glycoprotein gene fragments F and HN of an isolated strain JS-5-05-Go of Newcastle disease virus with high reproductive performance with the corresponding fragments of the ZJ1 strain of Newcastle disease virus of goose origin, so that the recombinant virus NDV-VII is obtained. The VII gene type of Newcastle disease virus A-NDV-VII which is highly attenuated is rescued after the attenuated mutation of the F gene of the recombinant virus. And the virus has a higher reproduction titer on chicken embryo. The invention is suitable for a mass production of vaccine, which can be used for the manufacture of vaccine.
Owner:YANGZHOU UNIV
Reverse genetic operation system of New castle disease LaSota vaccine strain and its applciation
The present invention is reverse genetic operation system of Newcastle disease Lasota low virulent vaccine strain and its application. The system includes one transcription plasmid including the genome cDNA sequence of the low virulent vaccine strain; one or several transcription aiding plasmids including the cDNA sequence coding the nucleoprotein of the low virulent vaccine strain, the cDNA sequence coding the phosphoprotein of the low virulent vaccine strain and the cDNA sequence coding the large polymerase protein of the low virulent vaccine strain; and the host cell of the Newcastle disease Lasota low virulent vaccine strain. Wild viral strain is obtained by means of the reverse genetic operation system. The present invention lays firm foundation for further development of Newcastle disease virus live carrier vaccine and Newcastle disease virus related research.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
A type foot-and-mouth disease recombinant vaccine strains and preparation method and application thereof
ActiveCN103266091AMultiple phenotype improvements and enhancedPhenotype Improvement and EnhancementMicroorganism based processesAntiviralsAntigenDisease
The invention relates to A type foot-and-mouth disease recombinant vaccine strains prepared by using a reverse genetic manipulation technology and a preparation method and application of the strains. One strain is an A type foot-and-mouth disease recombinant vaccine strain with high titer, antigen matching property and immune protection rate, and the other strain is an A type foot-and-mouth disease recombinant non-pathogenic vaccine strain with high titer, antigen matching property and immune protection rate and without pathogenicity for a host; an antigen nucleotide sequence of each of the vaccine strains is shown as SEQ ID NO: 1; eukaryotic plasmids of viruses can be saved by using a reverse genetic manipulation system; after pigs and cattle are immunized by using the inactivated vaccines prepared from the prepared recombinant vaccine strains, the bodies can be effectively stimulated to produce immune response, and an immune protection effect is provided for the bodies of the pigs and the cattle; through a 10,000-times cattle median infectious dose (BID50) challenge assay of A type AISA topological strains, the immune protection rate reaches 100 percent, and the median protective dose (PD50) is 10.81 to 13.59; and the recombinant vaccine strains can be applied to prevention and control of A type foot-and-mouth disease viruses of China and neighboring countries.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Attenuated influenza NS1 variants
Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.
Owner:UNIVERSITY OF SASKATCHEWAN
Attenuated influenza NS1 variants
InactiveUS20080050402A1Easy to produceSsRNA viruses negative-senseBiocidePhosphatidylinositolPhospholipid
Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.
Owner:UNIVERSITY OF SASKATCHEWAN
Method for expanding antigen spectrum of foot-and-mouth disease vaccine strain by reverse genetic operation and preparation method of vaccine
ActiveCN101948811AHigh protection rateBroad antigen spectrumVirus peptidesMicroorganism based processesImmune effectsSoutheast asia
The invention relates to a method for expanding the antigen spectrum of a foot-and-mouth disease vaccine strain by reverse genetic operation and a preparation method of a vaccine. The amino acid sequence of the VP3 and VP1 structural proteins of the foot-and-mouth disease virus strain of the invention is represented by the amino acid residues from a position 304 to a position 736 in SEQ ID No.4. Experiments show that the vaccine prepared from the mutant virus strain obtained by the invention can resist porcine epidemic viruses of China O / TL / Taiwan / 97 lineage, Pan-Asia O / China / 99 lineage and Southeast Asia Myanmar O / GS / 2010 / 98 lineage, has a characteristic of wide antigen spectrum, can immunize pigs and obviously improve the rate of protection against foot-and-mouth disease viruses which are of the same type and have antigenicity difference, achieves an immune effect of cross protection, and is expected to play an important role in the prevention and control of foot-and-mouth disease.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Recombinant low-virulent vaccine strain of chicken infectious bursal disease viruses (IBDV) and application thereof
ActiveCN101935637ANon-pathogenicGood spiritsViral antigen ingredientsMicroorganism based processesProtective antigenOrganism
The invention discloses a recombinant low-virulent vaccine strain of chicken infectious bursal disease viruses (IBDV) and application thereof. In the invention, a major protective antigen gene VP2 of an epidemic superhigh virulent strain is cloned, the nucleotide of the gene VP2 is modified by mutation and then used for replacing a corresponding segment of a Gt genome of a low-virulent strain of the IBDV, so that the infectious clone of a recombinant genome of the IBDV is constructed, and the recombinant low-virulent vaccine strain is saved and identified by using an IBDV reverse genetic operation system. The microbial collection number of the vaccine strain is CGMCC No.3749. The recombinant low-virulent vaccine strain of the invention has high replicability, genetic stability and safety. The immune effect of the low-virulent vaccine strain of the invention is as good as that of the medium-virulent vaccine strain, but is superior to that of the low-virulent vaccine strain. The biological safety of the low-virulent vaccine strain of the invention is superior to that of the medium-virulent vaccine strain. As the vaccine strain, the recombinant low-virulent vaccine strain of the invention has the characteristics of high efficiency and low toxicity, is a good candidate vaccine strain and can be used for controlling chicken infectious bursal disease.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Genotype VII Newcastle disease virus marker vaccine strain and application thereof
ActiveCN104988124AHigh growth titerHigh biological propertiesViral antigen ingredientsMicroorganism based processesViral MarkersChick embryos
The invention discloses a genotype VII Newcastle disease virus marker vaccine strain and an application thereof, and belongs to the field of genotype VII Newcastle disease virus marker vaccine strain rescue and application. A built Newcastle disease virus reverse genetic operating platform is utilized for enabling NP protein of a G7 strain to miss 18 amino acids and conducting mutation on F-protein cleavage loci, and the highly-weak virulence and high-virus titer genotype VII Newcastle disease virus marker vaccine strain MG7-NPdelta18+Fmut is rescued through screening. The microbial preservation serial number is CCTCC NO: V201505. The marker vaccine strain has the biological characteristics of high growth titer and low virulence in chick embryos and is genetically stable. The immune protection test result shows that the marker vaccine strain is good in immunogenicity, capable of inducing high-level protective antibodies, and capable of completely protecting immunized chicken, can be used for preventing and controlling a currently-popular genotype VII Newcastle disease virus and lays the foundation of identifying vaccine immunity and wild virus infection.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife
InactiveUS7074413B2Reduce absorptionEnhance immune responseSsRNA viruses negative-senseVectorsWildlifeRecombinant vaccines
Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.
Owner:UNITED STATES OF AMERICA +1
Attenuated vaccine strain of VII type new castle disease virus with mutated L gene and preparation method thereof
ActiveCN104962526AHigh titerGenetically stableMicroorganism based processesViruses/bacteriophagesAntigenDisease
The invention relates to an attenuated vaccine strain of a VII type new castle disease virus with a mutated L gene which is produced by reverse genetic operation technology and a preparation method thereof, and the invention belongs to the fields of biological products and biological technology. The virulence of the attenuated vaccine strain of the VII type new castle disease virus with the mutated L gene is obviously decreased, simultaneously the attenuated vaccine strain has the characteristics of high titer, stable heritability and high matching with the antigen of the epidemic virus according to the chicken embryo experiment; the preparation method is suitable for large scale production of vaccines, and is used for producing vaccines; compared with the conventional vaccines (gene I and gene II types), the attenuated vaccine strain of the VII type new castle disease virus with the mutated L gene has wide application prospects in the aspects of morbidity and epidemic control of new castle disease.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Preparation method for triple inactivated vaccine of recombinant Newcastle disease, bird flu and infectious bronchitis
InactiveCN106390112AHigh reproductive titerEasy to produceSsRNA viruses negative-senseSsRNA viruses positive-senseInfectious bronchitisBird flu
The invention provides a preparation method for a triple inactivated vaccine of recombinant Newcastle disease, bird flu and infectious bronchitis. The technical scheme is realized by gene modification of a Newcastle disease virus (DNV) LaSota strain. A recombinant NDV low virulent strain (rLaSota strain) is taken as a vector, firstly an S1 gene of a chicken infectious bronchitis virus (IBV) is inserted between F-HN, a recombinant NDV rLaSota / S1 expressing an S1 protein is constructed by utilizing a reverse genetic technology, and a result shows that rLaSota can serve as a live vector for stably expressing the S1 protein; secondly a recombinant NDV rLaSota / S1-HA expressing an HA gene is constructed, namely, the HA gene is inserted between P-M of the recombinant NDV rLaSota / S1; and thirdly immunogenicity assessment is performed. A result shows that the triple inactivated vaccine of the recombinant Newcastle disease, the bird flu and the infectious bronchitis, prepared through a conventional inactivated vaccine process has relatively good protection effects for the Newcastle disease, the bird flu and the infectious bronchitis.
Owner:TIANJIN RINGPU BIO TECH
Efficient cell culture system for hepatitis C virus genotype 5A
Owner:HVIDOVRE HOSPITAL
Peste des petits ruminants virus (PPRV) reverse genetic operating system and application thereof
ActiveCN102071218ALow costReduce labor costsInactivation/attenuationVector-based foreign material introductionComplementary deoxyribonucleic acidFull length cdna
The invention relates to a peste des petits ruminants virus (PPRV) reverse genetic operating system and an application thereof. The PPRV reverse genetic operating system comprises a transcription plasmid and one or more helper plasmids, wherein the transcription plasmid can express the genome full-length cDNA (complementary deoxyribonucleic acid) sequence of the PPRV; and the helper plasmid(s) can express nucleoprotein (N), phosphoprotein (P) and polymerase large protein (L) of the PPRV, and virus replication-permitting host cells of the PPRV. By using the PPRV reverse genetic operating system, the recombined PPRV is successfully saved. The establishment of the PPRV reverse genetic operating technical platform provides an excellent technical platform for the development of PPRV live vector vaccines and the fundamental research related to PPRV.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Rabies Virus Vector Systems and Compositions and Methods Thereof
ActiveUS20080274130A1Facilitated virus recoveryEfficient expressionSsRNA viruses negative-sensePeptide/protein ingredientsVector systemRabies virus strain
Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and / or ERA derivative strain viruses, nucleic acids and / or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Reverse genetic system for Rift Valley fever virus and uses thereof
ActiveUS20070122431A1SsRNA viruses negative-senseViral antigen ingredientsAntiviral drugRna expression
The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, the present invention discloses the use of this system in the development of anti-Rift Valley fever virus vaccines, screening of antivirals testing for anti RVF immune response and developing marker vaccines for Rift Valley fever virus. We also claim the utility of this approach to other phleboviruses.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Gene VIb subtype Rubulavirus Newcastle disease virus attenuated strain VIbI4 and construction method thereof
ActiveCN102776156AImprove reproductive performanceSuitable for mass productionMicroorganism based processesViruses/bacteriophagesNewcastle disease virus NDVEncephalitis Viruses
The invention relates to gene VIb subtype Avian pneumo-encephalitis virus attenuated strain VIbI4 and a construction method thereof. The preserving number of the gene VIb subtype scriber set Avian pneumo-encephalitis virus attenuated strain VIbI4 is CGMCCNo: 6149. The gene VIb subtype Rubulavirus Newcastle disease virus attenuated strain VIbI4 and the construction method thereof relate to a technology for applying reverse genetics; and the method comprises the following steps: carrying out mutation on an F gene by using a transcription carrier Ptvt / 071204 containing Avian pneumo-encephalitis virus JS / 07 / 04 / Pi full gene genome from pigeons so as to obtain to a transcription carrier ApTVT / 071204, and then substituting corresponding parts on the ApTVT / 071204 by the NP, P and L genetic fragments of Avian pneumo-encephalitis virus rNDV / I4 so as to obtain recombinant plasmids ApTVT / VIbI4, wherein the plasmids successfully save a recombinant virus VIbI4 after transfecting a BSR-T7 / 5 cell together with auxiliary plasmids. The virus is relatively high in propagating titre, is suitable for large-scale production of vaccines and can be used for manufacturing vaccines.
Owner:YANGZHOU UNIV
Application of OsWRKY28 transcription factor gene of rice in improvement of plant disease resistance
ActiveCN102816773AIncrease resistanceFermentationGenetic engineeringDiseaseGenetically modified rice
The invention belongs to the field of plant genetic engineering and discloses application of OsWRKY28 transcription factor gene of rice in improvement of plant disease resistance. In research of functions of the WRKY transcription factor gene OsWRKY28 of rice as shown inthe SEQ ID NO.1 by means of a reverse genetics method, the OsWRKY28 transcription factor gene is found to have positive regulation function for resistance to rice banded sclerotial blight. The OsWRKY28 transcription factor gene is planted on a proper plant expressing carrier to convert cells or rice, and resistance of obtained rice with OsWRKY28 excessive-expression transcription factor to the banded sclerotial blight is evidently improved. Accordingly, disease resistance of rice and other crops can be improved by the OsWRKY28 gene, and new varieties of transgenosis plants resistant to the banded sclerotial blight can be cultured.
Owner:SUN YAT SEN UNIV
Indicator gene used in TRV-mediated gene silencing system as well as construction method and application of carrier thereof
InactiveCN104480124AEasy to buildSignificant silent phenotypeFermentationVector-based foreign material introductionNicotiana tabacumGene carrier
The invention discloses an indicator gene used in a TRV-mediated gene silencing system, and the base sequence of the indicator gene is shown in SEQ ID NO:1. Virus induced gene silencing in the invention is a good tool for studying plant gene functions by using reverse genetics; according to the invention, an extremely good indicator gene carrier is provided for a tobacco rattle virus induced gene silencing technology; and the indicator gene carrier is simple in construction, significant in silencing phenotype and lasting in trait expression, and achieves a good indication effect on quick gene function researches.
Owner:ZHENGZHOU UNIV
Newcastle disease chimeric virus marker vaccine strain as well as construction method and application thereof
ActiveCN111575247AImprove growth characteristicsImproving immunogenicitySsRNA viruses negative-senseViral antigen ingredientsF proteinChick embryos
The invention relates to a Newcastle disease chimeric virus marker vaccine strain as well as a construction method and application thereof, and belongs to the field of rescue and application of Newcastle disease chimeric vaccine strains. A Newcastle disease virus reverse genetic operation platform is utilized to mutate an F protein cleavage site of a Newcastle disease gene GVII type strain into acleavage site of an attenuated strain, F and HN genes of a mutated gene VII type Newcastle disease strain and NP, P, M and L of a gene II type NDV La Sota strain construct a full-length chimeric cDNAsequence, and a 18bp nucleotide marker sequence is inserted into a non-coding region between P and M. A Newcastle disease chimeric virus NDV DC strain is obtained through transfection cell rescue. Theconstructed chimeric virus can reach relatively high culture titer in chick embryos and cells. The chimeric strain contains envelope surface glycoprotein of the gene VII type Newcastle disease strain, contains a skeleton of the gene II type strain, and has immunogenicity of the Newcastle disease gene VII type strain and high reproduction and high safety characteristics of the gene II type La Sotastrain.
Owner:ZHEJIANG VBIOSCI INC +1
ST cell lines for stably expressing T7 RNA polyase, constructing process and applications thereof
InactiveCN101285054AEnzymesVector-based foreign material introductionMicroorganism preservationFluorescence
The invention discloses a cell line ST / T7 capable of stably expressing T7RNA polymerase, the microorganism preservation number of which is: CGMCC No.24444. In the invention, a T7RNA polymerase gene is inserted into a eukaryotic expression vector pIRES2-EGFP to get the pIRES2-EGFP-T7 to transfect ST cells to obtain the cell line ST / T7 capable of stably expressing T7RNA polymerase. Through RT-PCR detection, expression plasmid containing a red fluorescent protein gene controlled by T7 promotors can be used to transfect the cell line so as to observe the expression of red fluorescent protein in a transcription product amplified form a ST / T7 cell to the T7RNA polymerase. The cell line ST / T7 can provide reverse T7RNA polymerase for use in reverse genetic manipulation of RNA-virus such as hog cholera virus, etc., and can be used as transcription and expression systems in vitro for research on genic structures and functions.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Application of OsNMCP1 gene in controlling drought tolerance in rice
The invention belongs to the technical field of plant gene engineering, particularly relates to application of OsNMCP1 gene in controlling drought tolerance in rice. According to the invention, a candidate gene screening method is adopted to clone a rice drought-tolerant response gene OsNMCP1 by reverse genetics. The nucleotide sequence of the gene is shown in SEQ NO:1, and the protein sequence encoded by the gene is shown in SEQ NO:3. The phenotypic identification of drought stress at seedling stage and heading stage indicates that overexpression of OsNMCP1 gene causes an improvement of the drought resistance of transgenic rice, while the deletion mutation of OsNMCP1 gene results in a significant decrease of rice drought resistance. In the invention, the biological function of the gene and the pathways and methods of application with the same are demonstrated.
Owner:HUAZHONG AGRI UNIV
Efficient cell culture system for hepatitis c virus genotype 1a and 1b
The present inventors developed hepatitis C virus 1a / 2a and 1b / 2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a / 2a and 1b / 2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and / or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis. The inventors in addition demonstrate the use of the developed systems for screening of antiviral substances in vitro and functional studies of the virus, e.g. identification of receptors required for HCV entry
Owner:HVIDOVRE HOSPITAL
Reverse genetic system for rift valley fever virus and uses thereof
The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, the present invention discloses the use of this system in the development of anti-Rift Valley fever virus vaccines, screening of antivirals testing for anti RVF immune response and developing marker vaccines for Rift Valley fever virus. We also claim the utility of this approach to other phleboviruses.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Influenza B virus Vero cell productive adaptive strain and preparation and application thereof
ActiveCN101619306AImprove protectionOvercome deficienciesInactivation/attenuationMicroorganism based processesTiterInfluenza vaccine
The invention provides an influenza B virus Vero cell productive adaptive strain and a preparation method and application thereof. The influenza B virus Vero cell productive adaptive strain is named as B / Yunnan / 2 / 2005va(B) with a preserved number of CGMCC No.2931. The virus strain can be continuously subcultured on the Vero cell, and a clotting titer can be kept over 1: 512. Through detecting, the virus strain is the influenza B virus, belonging to a Yamagata pedigree. The virus strain includes eight genetic fragments of the influenza B virus and has the characteristic of continuously producing the Vero cells. On the one hand, the virus strain is inoculated in the Vero cell, the supernate of a culture is collected to obtain a influenza B virus vaccine which has favorable immunogenicity and proactive effects through an experiment; on the other hand, the virus strain also can be used as a donor virus strain which is reassorted through a natural selective pressure or a reverse genetics to obtain the adaptive strain of an epidemic strain on the Vero cell, thereby an epidemic strain Vero cell influenza vaccine is prepared.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Rabies virus Flury-LEP vaccine strain reverse genetic operating system and LEP green fluorescent protein recombination viral vector
InactiveCN101586120AMicrobiological testing/measurementMicroorganism based processesPhosphoric acidViral vector
The invention relates to a rabies virus Flury-LEP vaccine strain reverse genetic operating system comprising a recombination vector for coding LEP full length genome cDNA and an auxiliary plasmid system thereof, wherein, the auxiliary plasmid system respectively codes nucleoprotein of LEP, phosphoric acid protein P and polyase protein L. the invention also relates to LEP green fluorescent protein recombination viral vector built by the reverse genetic operating system, concretely, the rabies virus Flury-LEP vaccine strain reverse genetic operating system is pCI-LEP and auxiliary plasmid systems pCAGG-N, pCAGG-P and pCAGG-L, the LEP green fluorescent protein recombination viral vector is pCI_LEP_EGEP. The invention also relates to recombination viruses rescued by the rabies virus Flury-LEP vaccine strain reverse genetic operating system and the LEP green fluorescent protein recombination viral vector, and applications thereof.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Recombinant newcastle disease vaccine candidate rAI4-penton to express avian adenovirus penton protein and construction method thereof
InactiveCN108728419ASuitable for mass productionImprove reproductive performanceFermentationDsDNA virusesEmbryoAvian adenovirus
The invention relates to recombinant newcastle disease vaccine candidate rAI4-penton to express avian adenovirus penton protein and a construction method thereof. newcastle viral strain rAI4-penton iscollected under CGMCC No: 15492. The construction method includes: using a reconstructed reverse genetics operating platform of a newcastle attenuated strain to penton gene sequence of avian adenovirus into genome full-length transcription vector pNDV / rAI4 of the strain AI4 so as to obtain recombinant newcastle viral genome full-length cDNA clone pNDV / rAI4-penton, and performing transfecting to obtain recombinant viral rAI4-penton that successfully express penton protein. The recombinant virus rAI4-penton has high breeding titer on chicken embryos, can stabilize the penton protein even aftercontinuous passage, is suitable for large-scale production of vaccines, and is suitable for making vaccines.
Owner:YANGZHOU UNIV
Efficient cell culture system for hepatitis c virus genotype 6a
InactiveUS20110059512A1Raise the potentialSsRNA viruses positive-senseSugar derivativesSequence analysisHCV Genotyping
The present inventors developed hepatitis C virus 6a / 2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a / 2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a / 2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analyses.
Owner:HVIDOVRE HOSPITAL
Reverse Genetics System
The complete genomic sequence of maize fine streak virus (MFSV), a negative-strand RNA virus that infects plants and insects, is disclosed. The inventors have characterized the MFSV genome and identified the leader and trailer sequences, seven open reading frames as well as the functions of some of the encoded proteins, and the gene junction sequences and their functions. Using various functionally important components of the MFSV genome, the inventors have demonstrated that a reverse genetics system of using cloned cDNA to produce infectious viruses can be developed for plant negative-strand RNA viruses. Methods of using the reverse genetic system to produce wild-type or recombinant plant negative-strand RNA viruses, to express genes of interest, and to screen for agents that may affect the production and function of the viruses are disclosed. Further disclosed are various nucleic acid constructs, vectors, genetically engineered cells, and kits useful in the reverse genetics system.
Owner:WISCONSIN ALUMNI RES FOUND
Influenza A virus Vero cell adapted strain and application thereof
ActiveCN101560503ATo satisfy the market's needsAvoid reduced vaccine efficacyInactivation/attenuationMicroorganism based processesHemagglutininReassortment
The invention discloses an influenza A virus Vero cell adapted strain and application thereof. The influenza A virus Vero cell adapted strain is named as A / Yunnan / 1 / 2005Va(H3N2), and the preserving number of the strain is CCTCC NO:V200514. The strain comprises an H3 subgroup hemagglutinin gene, an N2 subgroup neuraminidase gene and 6 internal genes for high yield of characteristic influenza viruses on Vero cells. The blood coagulation titer can be maintained at more than 1,024 by continuous subculturing of the strain on the Vero cells. The strain can be taken as a donor strain and subjected to genetic reassortment with an epidemic strain, or reverse genetics technology is adopted to perform genetic reassortment on the 6 internal genes and 2 surface protein genes of the epidemic strain to obtain the Vero cell adapted strain of the epidemic strain, and finally the adapted strain is used for preparing a Vero cell influenza vaccine or a Vero cell pandemic influenza vaccine.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com